You are here: Industry Insights > GBM

News List

Moleculin Announces Positive Interim Results in Adult Glioblastoma Clinical Trial americanpharmaceuticalreview
October 19, 2020
Moleculin Biotech announced additional preliminary data from the Phase 1 clinical trial of its immuno-stimulating STAT3 inhibitor, WP1066, in patients with glioblastoma (GBM).
DelMar Updates Clinical Trial of VAL-083 for Adjuvant Treatment of Brain Tumors americanpharmaceuticalreview
May 07, 2020
DelMar Pharmaceuticals has enrolled 22 patients in the adjuvant arm of the Company's ongoing Phase 2 clinical study investigating adjuvant treatment (pre-temozolomide -- or TMZ -- maintenance therapy) of MGMT-unmethylated glioblastoma multiforme (GBM) ...
Regorafenib to be tested in brain cancer patients in multi-arm cooperation trial worldpharmanews
June 24, 2019
Regorafenib to be tested in brain cancer patients in multi-arm cooperation trial.
Bayer’s Regorafenib is the First Drug to Enter GBM AGILE americanpharmaceuticalreview
November 19, 2018
The Global Coalition for Adaptive Research (GCAR) and Bayer announced that Bayers regorafenib will be the first drug to
Ziopharm Oncology Announces Immuno-oncology Clinical Supply Agreement with Regeneron pharmafocusasia
November 13, 2018
Ziopharm Oncology, Inc.,today announced a clinical supply agreement with Regeneron Pharmaceuticals, Inc. to evaluate Ziopharm’s Ad-RTS-hIL-12 plus veledimex in combination with Regeneron’s PD-1 antibody Libtayo® (cemiplimab-rwlc) to treat patients with re
Ziopharm Oncology Announces Immuno-oncology Clinical Supply Agreement with Regeneron pharmafocusasia
November 13, 2018
Ziopharm Oncology, Inc.,today announced a clinical supply agreement with Regeneron Pharmaceuticals, Inc. to evaluate Ziopharm’s Ad-RTS-hIL-12 plus veledimex in combination with Regeneron’s PD-1 antibody Libtayo® (cemiplimab-rwlc) to treat patients with re
Hansa Medical Receives Positive Opinion for Orphan Drug Designation in the EU for Imlifidase for Anti-GBM Disease firstwordpharma
October 25, 2018
Hansa Medical Receives Positive Opinion for Orphan Drug Designation in the EU for Imlifidase for Anti-GBM Disease
DelMar Announces Accelerated Patient Enrollment of Trial in MGMT-unmethylated Recurrent GBM americanpharmaceuticalreview
June 27, 2018
DelMar updated patient enrollment data for its Phase 2 open-label clinical trial of VAL-083 in bevacizumab (Avastin)-naïve recurrent glioblastoma multiforme (rGBM) patients with MGMT-unmethylated status.
CANbridge Receives Approval to Commence CAN008 Phase II/III Trial in Glioblastoma Multiforme (GBM) in China biospace
April 13, 2018
CANBridge Life Sciences announced that the China Food and Drug Administration (CFDA) has approved the Investigational New Drug (IND) application for a Phase II/III clinical study of lead candidate, CAN008

Previous page 1 2 Next page